ClinicalTrials.gg
CompletedNCT00698516Updated Mar 27, 2012Results posted

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

A Phase 2 interventional study of Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) in Recurrent Small-cell Lung Cancer (SCLC) and Lung Cancer, Small Cell, sponsored by GlaxoSmithKline. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-27.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.

Enrollment
14th of 28
50 · median 44
Started
2008
the only one that year
Phase 2
11 of 29
1 open now
Registered
22nd of 29
by date
Lead sponsor
7 of 29
GlaxoSmithKline

Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2008, is one of 11 in phase 2, and was the 22nd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing topotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.

03

Conditions studied

  • Recurrent Small-cell Lung Cancer (SCLC)
  • Lung Cancer, Small Cell

Keywords

  • Bevacizumab
  • Small Cell Lung Cancer (SCLC)
  • Topotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of SCLC.
  • First recurrence of SCLC after therapy with one prior chemotherapy regimen at initial diagnosis.
  • SCLC of any duration (both sensitive and resistant relapse).
  • performance status of \</= 2.
  • Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.
  • No prior therapy with bevacizumab or any other VEGF inhibitor or topotecan

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled emesis, regardless of etiology.
  • Active uncontrolled infection.
  • GI conditions or drugs that could impact absorption of oral topotecan.
  • Known to any component of topotecan capsule or compounds chemically related to topotecan.
  • Uncontrolled hypertension with BP>150/100.
  • Prior h/o hypertensive crisis or encephalopathy.
  • Grade II or greater congestive heart failure.
  • H/O myocardial infarction within 6 months.
  • H/O stroke or within 6 months.
  • H/O thrombotic or hemorrhagic disorders.
  • vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months.
  • Major surgical procedure, open , or significant traumatic injury within 28 days.
  • Anticipation of need for major surgical procedure during the study.
  • Minor surgical procedures within 7 days prior to treatment start (placement of vascular access devices is permitted).
  • H/O abdominal fistula, GI perforation, or intra-abdominal abscess within prior 6 months. Serious, non-healing wound, active ulcer, or untreated bone fracture. - H/O hemoptysis within prior 1 month.
  • Concurrent radiotherapy.
  • H/O whole lung radiation within 90 days prior to start of treatment.
  • Presence or h/o central nervous system or .
  • H/o another other than SCLC.
  • Concurrent chemotherapy, immunotherapy, or therapy for the treatment of small cell lung cancer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Open label, Single arm

    Oral topotecan + IV Bevacizumab

    Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)

Interventions

  • DrugOral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)

    Drug page: Topotecan

    2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression-free Survival (PFS) at 3 Months

    PFS = time from initiation of drug to time of first disease progression/death due to any cause. Progression assessed using Response Evaluation Criteria (RECIST): \>=20% increase in sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion(s). If participant did not progress or die, the time of initiation of post-treatment anti-cancer therapy or time of last contact used. PFS at 3 months calculated by taking the Kaplan-Meier (KM) estimate at 90 days from the initiation of treatment. SE = standard error.

    Time frame: 3 months

Secondary outcomes

  1. PFS - Overall

    Progression-free survival at any site was defined as the time from initiation of investigational product to the time of first documented disease progression or death due to any cause. Progression was assessed using the RECIST guidelines: \>= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion (s). For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.

    Time frame: Baseline to disease progression or death (up to 82.4 weeks)

  2. Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

    Tumor response was determined using the RECIST guidelines.CR, disappearance of all target lesions; PR, \>=30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since treatment started; PD, \>=20% increase in sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Baseline to disease progression or death (up to 82.4 weeks)

  3. Number of Participants With a Tumor Response (CR and PR)

    Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.

    Time frame: Baseline to disease progression or death (up to 82.4 weeks)

  4. Duration of Tumor Response (CR and PR)

    Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Duration of response is defined as the time from start of response (CR or PR) until progression or death due to any cause. For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.

    Time frame: Baseline to disease progression or death (up to 82.4 weeks)

  5. Time to Tumor Response (CR and PR)

    Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Time to response is defined as the time from initiation of investigational product to the time of first documented response (CR or PR).

    Time frame: Baseline to disease progression or death (up to 82.4 weeks)

  6. Overall Survival

    Overall survival is defined as the time from initiation of investigational product to death due to any cause. For participants who did not die, the time of last contact was used.

    Time frame: Baseline to disease progression or death (up to 82.4 weeks)

07

Results

Posted Feb 3, 2011

Participant flow

Participant flow — Overall Study
MilestoneTopotecan and Bevacizumab
Started50
Completed45
Not completed5
Withdrew: Study termination2
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPercentage of Participants With Progression-free Survival (PFS) at 3 Months

PFS = time from initiation of drug to time of first disease progression/death due to any cause. Progression assessed using Response Evaluation Criteria (RECIST): \>=20% increase in sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion(s). If participant did not progress or die, the time of initiation of post-treatment anti-cancer therapy or time of last contact used. PFS at 3 months calculated by taking the Kaplan-Meier (KM) estimate at 90 days from the initiation of treatment. SE = standard error.

Time frame:
3 months
Reported as:
Number · percentageof participants
Percentage of Participants With Progression-free Survival (PFS) at 3 Months
percentageof participantsTopotecan and Bevacizumab
Percentage of Participants With Progression-free Survival (PFS) at 3 Months65
Statistical analysis
  • Topotecan and Bevacizumab · Z statistic · p = 0.017 (Historical data in target population showed 3-month PFS rates of \<=50%. Oral topotecan with IV bevacizumab would provide clinically meaningful improvement in 3-month PFS if it could demonstrate a 40% improvement relative to the historical data.) · Greenwood variance: 65.0 · 95% CI 49.3 to 76.9Z statistic was used to reject the null hypothesis provided Z\>=1.65, where Z = (KM estimate at 3 months - null hypothesis value \[50%\])/Greenwood SE.
SecondaryPFS - Overall

Progression-free survival at any site was defined as the time from initiation of investigational product to the time of first documented disease progression or death due to any cause. Progression was assessed using the RECIST guidelines: \>= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion (s). For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.

Time frame:
Baseline to disease progression or death (up to 82.4 weeks)
Reported as:
Median · weeks
PFS - Overall
weeksTopotecan and Bevacizumab: Resistant ParticipantsTopotecan and Bevacizumab: Sensitive ParticipantsTopotecan and Bevacizumab: All Participants
PFS - Overall12.64 (6.43 to 21.43)27.14 (16.14 to 32.57)17.43 (13.14 to 25.00)
SecondaryNumber of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

Tumor response was determined using the RECIST guidelines.CR, disappearance of all target lesions; PR, \>=30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since treatment started; PD, \>=20% increase in sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Baseline to disease progression or death (up to 82.4 weeks)
Reported as:
Number · participants
Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
participantsTopotecan and Bevacizumab: Resistant ParticipantsTopotecan and Bevacizumab: Sensitive ParticipantsTopotecan and Bevacizumab: All Participants
CR000
PR268
SD91120
PD9413
Unknown369
SecondaryNumber of Participants With a Tumor Response (CR and PR)

Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.

Time frame:
Baseline to disease progression or death (up to 82.4 weeks)
Reported as:
Number · participants
Number of Participants With a Tumor Response (CR and PR)
participantsTopotecan and Bevacizumab: Resistant ParticipantsTopotecan and Bevacizumab: Sensistive ParticipantsTopotecan and Bevacizumab: All Participants
Number of Participants With a Tumor Response (CR and PR)268
SecondaryDuration of Tumor Response (CR and PR)

Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Duration of response is defined as the time from start of response (CR or PR) until progression or death due to any cause. For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.

Time frame:
Baseline to disease progression or death (up to 82.4 weeks)
Reported as:
Median · weeks
Duration of Tumor Response (CR and PR)
weeksTopotecan and Bevacizumab
Duration of Tumor Response (CR and PR)20.6 (15.6 to 41.0)
SecondaryTime to Tumor Response (CR and PR)

Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Time to response is defined as the time from initiation of investigational product to the time of first documented response (CR or PR).

Time frame:
Baseline to disease progression or death (up to 82.4 weeks)
Reported as:
Median · weeks
Time to Tumor Response (CR and PR)
weeksTopotecan and Bevacizumab
Time to Tumor Response (CR and PR)5.8 (5.3 to 12.7)
SecondaryOverall Survival

Overall survival is defined as the time from initiation of investigational product to death due to any cause. For participants who did not die, the time of last contact was used.

Time frame:
Baseline to disease progression or death (up to 82.4 weeks)
Reported as:
Median · weeks
Overall Survival
weeksTopotecan and Bevacizumab: Resistant ParticipantsTopotecan and Bevacizumab: Sensitive ParticipantsTopotecan and Bevacizumab: All Participants
Overall Survival26.4 (18.1 to 38.0)37.0 (30.6 to 48.0)32.0 (26.4 to 39.3)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Topotecan and Bevacizumab—18/50 (36%)50/50 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventTopotecan and Bevacizumab
PneumoniaInfections and infestations4/50
DiarrhoeaGastrointestinal disorders3/50
SepsisInfections and infestations2/50
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/50
Febrile neutropeniaBlood and lymphatic system disorders2/50
ThrombocytopeniaBlood and lymphatic system disorders2/50
NauseaGastrointestinal disorders2/50
VomitingGastrointestinal disorders2/50
DehydrationMetabolism and nutrition disorders2/50
Inappropriate antidiuretic hormone secretionEndocrine disorders2/50
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTopotecan and Bevacizumab
FatigueGeneral disorders32/50
NauseaGastrointestinal disorders30/50
DiarrhoeaGastrointestinal disorders27/50
AnaemiaBlood and lymphatic system disorders27/50
Decreased appetiteMetabolism and nutrition disorders24/50
NeutropeniaBlood and lymphatic system disorders22/50
ThrombocytopeniaBlood and lymphatic system disorders21/50
VomitingGastrointestinal disorders19/50
ConstipationGastrointestinal disorders17/50
CoughRespiratory, thoracic and mediastinal disorders15/50

Baseline characteristics

Age Continuous
Age Continuous(Years)Topotecan and Bevacizumab
Mean60.8 ± 10.75
Sex: Female, Male
Sex: Female, Male(Participants)Topotecan and Bevacizumab
Female26
Male24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Topotecan and Bevacizumab
White43
African American/African Heritage6
White and Mixed Race1
08

Study locations

16 sites
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Gainesville, Florida 32605, United States
  • GSK Investigational Site
    Naples, Florida 34119, United States
  • GSK Investigational Site
    Athens, Georgia 30607, United States
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Marietta, Georgia 30060, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
  • GSK Investigational Site
    Memphis, Tennessee 38104, United States
  • GSK Investigational Site
    Memphis, Tennessee 38120, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Seattle, Washington 98101-2795, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin Lung Cancer. 2013 Jul;14(4):356-63. doi: 10.1016/j.cllc.2012.12.003. Epub 2013 Feb 4. PubMed 23391616 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2008
First posted
Jun 17, 2008
Start
Jul 2008
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Feb 3, 2011
Last update
Mar 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00698516
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 17, 2008
Start date
Jul 2008
Primary completion
May 2010
Completion
May 2010
Results posted
Feb 3, 2011
Last update
Mar 27, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Topotecan

Start the discussion